Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer: An Indian perspective

Gupta Sudeep, Chatterjee Sanjoy, Nigade Jagdish, Aggarwal Shyam, Singhal Manish, S. S. Alurkar, Kukreja Anil, B. K. Smruti, Nag Shona, Agarwal Amit, Agarwal Vijay, R. T. Chacko, Desai Chirag, Goswami Chanchal, Keechilat Pavithran, Patil Poonam, Prasad Krishna, Rajendranath Rejiv, R. R. Rao, T. P. SahooSingh Ashish, Singh Randeep, Srinivasan Sankar, Warrier Arun, Swarup Binay, Bhattacharya Priyanka, S. H. Advani

Research output: Contribution to journalReview article


Human epidermal growth factor receptor 2 (HER2)-positive is an aggressive subtype of breast cancer and has historically been associated with poor outcomes. The availability of various anti-HER2 therapies, including trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine (TDM-1), has remarkably improved the clinical outcomes in patients with HER2-positive metastatic breast cancer (mBC). However, there is a need to optimize treatment within this population, given the wide variability in clinical presentation. Additionally, geographical and socio-economic considerations too need to be taken into account. To clarify and collate evidence pertaining to HER2-positive metastatic breast cancer, a panel of medical and clinical oncologists from across India developed representative clinical scenarios commonly encountered in clinical practice in the country. This was followed by two meetings wherein each clinical scenario was discussed in detail and relevant evidence appraised. The result of this process is presented in this manuscript as evidence followed by therapeutic recommendations of this panel for management of HER2-positive mBC in the Indian population.

Original languageEnglish
Pages (from-to)368-379
Number of pages12
JournalIndian Journal of Medical and Paediatric Oncology
Issue number3
Publication statusPublished - 01-07-2018
Externally publishedYes


All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Oncology

Cite this